At the 26th Annual Prostate Cancer Foundation PCF Scientific Retreat Joaquin Mateo, Principal Investigator, and Translational Scientist at the Vall d'Hebron hospital in Barcelona joins Charles Ryan to discuss how PARP inhibitors are being integrated into the standard of care for prostate cancer, pivotal studies that are reporting and ongoing with PARP inhibitors, and important aspect of those studies that clinicians should integrate into his or her clinical daily life.
|